Capital Analysts LLC cut its position in shares of Atrion Co. (NASDAQ:ATRI) by 29.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 474 shares of the medical instruments supplier’s stock after selling 201 shares during the quarter. Capital Analysts LLC’s holdings in Atrion were worth $554,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the stock. Citadel Advisors LLC bought a new position in Atrion in the fourth quarter valued at approximately $269,000. Teacher Retirement System of Texas bought a new position in Atrion in the fourth quarter valued at approximately $323,000. Bank of Montreal Can grew its stake in Atrion by 25.7% in the fourth quarter. Bank of Montreal Can now owns 597 shares of the medical instruments supplier’s stock valued at $376,000 after purchasing an additional 122 shares in the last quarter. Voya Investment Management LLC grew its stake in Atrion by 10.2% in the second quarter. Voya Investment Management LLC now owns 755 shares of the medical instruments supplier’s stock valued at $486,000 after purchasing an additional 70 shares in the last quarter. Finally, Advisor Group Inc. grew its stake in Atrion by 5,826.7% in the third quarter. Advisor Group Inc. now owns 889 shares of the medical instruments supplier’s stock valued at $598,000 after purchasing an additional 874 shares in the last quarter. Institutional investors and hedge funds own 59.24% of the company’s stock.
Atrion Co. (NASDAQ ATRI) opened at $547.80 on Friday. The firm has a market capitalization of $1,079.44, a P/E ratio of 30.35 and a beta of 0.73. Atrion Co. has a one year low of $459.05 and a one year high of $694.00.
Separately, BidaskClub downgraded Atrion from a “hold” rating to a “sell” rating in a research note on Tuesday, December 12th.
TRADEMARK VIOLATION WARNING: “Capital Analysts LLC Decreases Position in Atrion Co. (ATRI)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/25/capital-analysts-llc-decreases-position-in-atrion-co-atri.html.
Atrion Company Profile
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.
Want to see what other hedge funds are holding ATRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atrion Co. (NASDAQ:ATRI).
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.